PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcophtBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Ophthalmology
 
BMC Ophthalmol. 2012; 12: 20.
Published online Jul 16, 2012. doi:  10.1186/1471-2415-12-20
PMCID: PMC3410804
High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study
Mansing Ratanasukon,corresponding author1 Patama Bhurayanontachai,1 and Pichai Jirarattanasopa1
1Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla province, 90110, Thailand
corresponding authorCorresponding author.
Mansing Ratanasukon: mratanasukon/at/yahoo.com; Patama Bhurayanontachai: patama103/at/yahoo.com.au; Pichai Jirarattanasopa: jpichai/at/hotmail.com
Received April 4, 2011; Accepted July 16, 2012.
Abstract
Background
To determine the efficacy of high-dose antioxidants in the acute stage of central serous chorioretinopathy (CSC).
Methods
This was a randomized placebo-controlled study. The patients with acute CSC (onset within 6 weeks) were randomized to receive either high-dose antioxidant tablets (study group A) or placebo tablets (control group B) for 3 months or until the complete resolution of subretinal fluid. After 3 months, additional treatment with laser or photodynamic therapy (PDT) was considered if any fluorescein leakage persisted. The outcomes measured were the changes in visual acuity (VA) and central macular thickness (CMT), the number of patients with subretinal fluid at each follow-up time, the number of patients with fluorescein leakage at the end of the 3rd month and patients who received additional treatments.
Results
Fifty-one of 58 patients (88%) completed the follow-up criteria. The baseline demographic data were comparable in both groups. At the end of the 3rd month, the VA and CMT showed no statistical difference between the groups but the patients in group A has less fluorescein leakage and additional treatments than in group B (p = 0.027 and 0.03).
Conclusion
The high-dose antioxidants for acute CSC did not show any benefits in VA and CMT. However, the drugs might decrease the chance for fluorescein leakage and additional treatments at the end of the 3rd month.
Keywords: Antioxidants, Central serous chorioretinopathy
Articles from BMC Ophthalmology are provided here courtesy of
BioMed Central